Company profile: Seelos Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapeutics, including: SLS-002 intranasal ketamine for acute suicidal ideation/behavior in MDD and PTSD; SLS-005 IV trehalose for ALS and spinocerebellar ataxia; SLS-009 targeting mutant/misfolded proteins in Huntington’s and Alzheimer’s via autophagy; SLS-004 SNCA gene therapy for Parkinson’s; SLS-007 peptide targeting alpha-synuclein aggregation.
Products and services
- SLS-002: Intranasal ketamine targets Acute Suicidal Ideation and Behavior in Major Depressive Disorder and Post-Traumatic Stress Disorder, leveraging nasal administration for acute intervention
- SLS-004: Gene therapy modulates the SNCA gene to modify alpha-synuclein expression in Parkinson’s Disease, focusing on targeted regulation of SNCA to influence disease-related protein expression
- SLS-005: Intravenous trehalose treats Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia, crosses the blood-brain barrier, and induces autophagy for neurodegenerative disease management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Seelos Therapeutics
Reverse Medical
HQ: United States
Website
- Description: Provider of commercial-stage medical devices focused on revascularizing patients experiencing acute ischemic stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverse Medical company profile →
Solvonis Therapeutics
HQ: United Kingdom
Website
- Description: Provider of biopharmaceutical research and development focused on treatments for addiction and mental health issues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solvonis Therapeutics company profile →
Anavex Life Sciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for cancer and neurological diseases, including ANAVEX 2-73 (blarcamesine), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) for Alzheimer's, Parkinson's, and Rett syndrome; ANAVEX 3-71 targeting sigma-1 and M1 muscarinic receptors for schizophrenia, Alzheimer's, and frontotemporal dementia; and the SIGMACEPTOR Discovery Platform for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anavex Life Sciences company profile →
Vycor Medical
HQ: United States
Website
- Description: Provider of medical devices for neurological brain and spinal surgical procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vycor Medical company profile →
EIP Pharma
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for neurodegenerative diseases, centered on neflamapimod, an oral p38 alpha inhibitor aimed at reversing synaptic dysfunction; conducting Phase 2b trials (RewinD-LB in dementia with Lewy bodies, REVERSE-SD in early-stage Alzheimer’s) and exploring stroke recovery by enhancing neural plasticity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EIP Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Seelos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Seelos Therapeutics
2.2 - Growth funds investing in similar companies to Seelos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Seelos Therapeutics
4.2 - Public trading comparable groups for Seelos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →